Search Results
Your search for ,Per matches 4038 pages
Showing 101 - 150Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers
Researchers leading the LORD trial of active surveillance for ductal carcinoma in situ (DCIS) described early results as “reassuring” in a presentation to the 15th European Breast Cancer Conference (EBCC15) in Barcelona (Abstract 2LBA). People diagnosed with DCIS have abnormal cells inside the milk ...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy, or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989, given as monotherapy or in combination with...
Using AI to Differentiate Primary Lung Squamous Cell Carcinomas From Metastases
A multipronged artificial intelligence (AI)–assisted approach integrated into routine molecular profiling identified 3.1% of cases submitted as lung squamous cell carcinoma as metastases from other origins, revealing a meaningful rate of misdiagnosis in this patient population, according to a...
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
On March 20, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma. The FDA also granted traditional...
Hypofractionated Locoregional RT in Early Breast Cancer
As reported in The Lancet by Rivera et al, 5-year results of a French phase III trial (UNICANCER HypoG-01) showed noninferiority of hypofractionated locoregional radiotherapy (RT) vs standard 5-week RT in reducing risk of postsurgery lymphedema in patients with early breast cancer. Study Details In ...
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response...
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges. This annual survey on...
Study Finds No Overall Increase in Cancer Risk After Medically Assisted Reproduction
Overall cancer incidence is similar between women who have used medically assisted reproduction and the general population, but certain cancers may occur at slightly higher rates, according to an Australian population–based cohort study published in JAMA Network Open by Vajdic et al. The...
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response after surgical resection or local ablation, based on the phase III KEYNOTE-937 trial.1 Presented at...
FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool
The U.S. Food and Drug Administration (FDA) has launched a new platform, called the FDA Adverse Event Monitoring System (AEMS), for analyzing adverse events from drugs and products. The platform consolidates multiple prior reporting systems in an effort to modernize and increase transparency into...
AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden
Integration of artificial intelligence (AI) into screening workflows increased the detection of breast cancer by 10.4% in the United Kingdom, according to the results of the GEMINI study published in Nature Cancer. Additionally, use of AI in different workflows led to reductions in workload by up...
SABCS 2025: High-Level Review of Select Data
The 2025 San Antonio Breast Cancer Symposium (SABCS 2025) featured some exciting presentations. The early breast cancer highlights at SABCS 2025 included the landmark lidERA trial, which explored the efficacy of the oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant...
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
In a European phase II/III trial (AXINET) reported in the Journal of Clinical Oncology, Garcia-Carbonero et al found that the addition of axitinib to long-acting octreotide appeared to show activity in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). Study Details The...
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
In a Chinese phase II trial (CHANCE2005/CARES-005) reported in the Journal of Clinical Oncology, Zhu et al found that the addition of camrelizumab and rivoceranib to transarterial chemoembolization (TACE) improved progression-free survival in patients with unresectable hepatocellular carcinoma....
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Quadrivalent human papillomavirus (HPV) vaccination led to a significantly reduced risk of invasive cervical cancer that was sustained through long-term follow-up, according to the results of a Swedish nationwide, register-based cohort study published in The BMJ. “This study provides evidence of...
Colorectal Cancer: ACS Report Shows Increasing Incidence, Mortality Rates in Younger Adults
Findings from the American Cancer Society's triennial report, Colorectal Cancer Statistics, 2026, show that rates of colorectal cancer are decreasing in older adults; however, rates of colorectal cancer incidence in younger adults continue to increase, with a greater proportion of these cancers...
Advanced Nonsquamous NSCLC: FDA Grants Accelerated Approval to Zongertinib
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain ...
SABCS 2025: Top Picks From a Breast Cancer Specialist
Among the high-quality abstract presentations at the annual San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his top picks for most...
Effect of Medicaid Expansion on Diagnosis, Treatment, and Outcomes in NSCLC
In a study reported in the Journal of Clinical Oncology, Zhao et al found that patients with non–small cell lung cancer (NSCLC) in Medicaid expansion states have had improvements in earlier diagnosis, early initiation of treatment, and survival. Study Details In the study, patients newly diagnosed...
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
On February 24, the U.S. Food and Drug Administration (FDA) granted traditional approval to the kinase inhibitor encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, ...
Microplastics Found in 90% of Prostate Cancer Samples
Microplastics and nanoplastics were identified in samples from 9 out of 10 patients with prostate cancer, with greater levels of these small plastic fragments inside tumors than in nearby normal tissue, according to findings from a small pilot study that will be presented at the upcoming 2026 ASCO...
Proximity to Nuclear Power Plants and Cancer Risk
U.S. counties located closer to operational nuclear power plants (NPPs) have higher rates of cancer mortality than those located farther away, according to a new study published by Alwadi et al in Nature Communications. The study is the first of the 21st century to analyze proximity to NPPs and...
Ultra-Hypofractionated vs Conventionally Fractionated RT for Localized Prostate Cancer—10-Year Outcomes
As reported in The Lancet Oncology by Nilsson et al, the 10-year analysis of the phase III HYPO-RT-PC trial confirmed the noninferiority of ultra-hypofractionated vs conventionally fractionated radiotherapy (RT) in failure-free survival in patients with localized prostate cancer. The previously...
Young-Onset Pancreatic Cancer: Can Alcohol Consumption Raise Risk?
In a nationwide Korean cohort study reported in the Journal of Clinical Oncology, Park et al found that risk of young-onset pancreatic cancer was associated with increased consumption of alcohol and increased frequency of alcohol consumption. Study Details In the study, a nationwide cohort of...
FDA Approves TTFields Device for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, noninvasive device that delivers alternating electrical fields, known as tumor treating...
Interval Cancer Rate With AI-Supported Mammography Screening
In a Swedish trial (MASAI) reported in The Lancet, Gommers et al found that artificial intelligence (AI)-supported mammography was noninferior to standard double reading without AI in identifying interval breast cancers in women undergoing breast cancer screening. Study Details In the study,...
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
Earlier this week, 25 health-care organizations proposed that the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-Kickback Statute that would allow clinical trial sponsors to financially support patients to offset indirect or nonmedical costs...
Early Findings From First Human Study of In Vivo CAR T in Myeloma
The first-in-human clinical trial of an in vivo CAR T-cell therapy for multiple myeloma has shown encouraging clinical outcomes at an early time point, with a safety profile and ease of administration that indicates the off-the-shelf KLN-1010 could be easily deployable, researchers from Australia...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib...
HPV Testing During Cervical Cancer Screening: Potential ‘Convenient and Noninvasive’ Method
Testing menstrual blood for human papillomavirus (HPV) could be a “robust alternative or replacement” for current cervical cancer screening by a clinician, according to findings from a Chinese study published by Tian et al in The BMJ. The researchers say using menstrual blood for HPV testing is...
Ultraprocessed Food Associated With Increased Mortality Risk in Cancer Survivors
Consumption of higher quantities of ultraprocessed food was associated with increased all-cause and cancer mortality rates in cancer survivors, irrespective of the quality of their diet, according to findings published in Cancer Epidemiology, Biomarkers & Prevention. “These results suggest...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Sako et al conducted a prognostic study to evaluate whether a fully automated deep-learning radiomic biomarker based on serial CT scans could improve prediction of overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. Their findings,...
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
A randomized, controlled clinical trial for artificial intelligence (AI)–supported mammography readings, called the MASAI trial, demonstrated that AI reads of mammogram scans led to fewer interval breast cancer diagnoses than with standard double reads by radiologists, according to findings...
Outcomes With Colorectal Cancer Screening Among Childhood Cancer Survivors Who Received Abdominopelvic Radiation
In a study reported in the Journal of Clinical Oncology, Yeh et al found that childhood cancer survivors who received abdominopelvic radiation, who are at increased risk of developing colorectal cancer, can benefit from early screening to reduce the risk of colorectal cancer and associated...
Colorectal Cancer: How Does Lifetime Alcohol Consumption Affect Risk?
Studies have demonstrated a link between alcohol consumption and an elevated risk of colorectal cancer. New research now reveals that higher lifetime alcohol consumption is also associated with a higher risk, especially for rectal cancer, and that quitting drinking can lower a person’s risk. The...
New Report Shows Colorectal Cancer Is Top Cause of Cancer Mortality in Those Under 50
A new study by American Cancer Society (ACS) researchers shows that overall cancer mortality in people younger than age 50 in the United States has decreased by 44%, from 25.5 per 100,000 people in 1990 to 14.2 in 2023. The progress is due to declines in mortality for four of the five leading...
A Battle With My Blood
Editor’s note: On November 22, 2025—the 62nd anniversary of her grandfather President John F. Kennedy’s assassination—Tatiana Celia Kennedy Schlossberg published an essay in The New Yorker detailing her diagnosis of acute myeloid leukemia with chromosome 3 inversion, a rare and aggressive subtype...
Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening
Repeated methodological flaws in published research result in misinformation that may cause eligible patients to forgo or not be offered lung cancer screening, according to a joint publication from the Society of Thoracic Surgeons (STS), American Society for Radiation Oncology (ASTRO), and American ...
Global Cancer Survival Gaps Assessed Using a Country-Level Machine-Learning Framework
A machine-learning model has calculated country-specific cancer mortality-to-incidence ratios and evaluated the factors that contribute the most to each country's survival gaps. Additionally, the artificial intelligence (AI) tool mapped out actions each country could take to improve cancer...
Genetic Predisposition to Higher Body Mass Index Linked to Mortality After Breast Cancer
In an observational cohort study published in JAMA Network Open, Bodelon et al examined whether inherited susceptibility to excess body weight influences long-term survival among breast cancer survivors. Using a polygenic score for body mass index (BMI), the investigators sought to determine...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine...
ACS Report Shows 5-Year Survival for All Cancers Combined Has Reached 70%
New data published by Siegel et al in the American Cancer Society’s (ACS) Cancer Statistics, 2026 report show that, for the first time, the 5-year survival rate for all cancers combined has reached 70% for individuals diagnosed during 2015 to 2021 in the United States. In addition, those diagnosed...
Anaplastic Glioma: Concurrent vs Adjuvant Temozolomide
As reported in The Lancet Oncology by van den Bent et al, the final analysis of the phase III CATNON trial has shown continued overall survival benefit with radiotherapy followed by 12 cycles of adjuvant temozolomide in patients with newly diagnosed 1p/19q non–co-deleted anaplastic gliomas;...
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer
In a European phase III trial (PORTEC-4a) reported in The Lancet Oncology, van den Heerik et al found that molecular profile–based adjuvant treatment produced favorable results in women with high-intermediate risk endometrial cancer and allowed patients with favorable risk to be spared adjuvant...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
